State Street Corp Design Therapeutics, Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 698,986 shares of DSGN stock, worth $2.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

698,986

Previous 695,224 0.54%

Holding current value

$2.34 Million

Previous $1.84 Million 52.88%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.27 - $4.03 $8,539 - $15,160	3,762 Added 0.54%	698,986 $2.82 Million
Q4 2023 Feb 14, 2024	BUY	$1.99 - $2.76 $4,976 - $6,902	2,501 Added 0.36%	695,224 $1.84 Million
Q3 2023 Nov 14, 2023	BUY	$2.05 - $8.14 $218,710 - $868,440	106,688 Added 18.21%	692,723 $1.63 Million
Q2 2023 Aug 14, 2023	SELL	$4.99 - $7.64 $626,210 - $958,766	-125,493 Reduced 17.64%	586,035 $3.69 Million
Q1 2023 May 15, 2023	SELL	$5.5 - $9.77 $12.8 Million - $22.7 Million	-2,325,932 Reduced 76.57%	711,528 $4.11 Million

Q4 2022 Feb 14, 2023	BUY	$7.86 - $17.2 $16.7 Million - $36.6 Million	2,127,991 Added 233.98%	3,037,460 $31.2 Million
Q3 2022 Nov 15, 2022	BUY	$14.09 - $25.57 $6.48 Million - $11.8 Million	459,688 Added 102.2%	909,469 $15.2 Million
Q2 2022 Aug 15, 2022	BUY	$9.91 - $17.33 $458,238 - $801,339	46,240 Added 11.46%	449,781 $6.3 Million
Q1 2022 May 16, 2022	BUY	$11.17 - $20.89 $684,497 - $1.28 Million	61,280 Added 17.9%	403,541 $6.52 Million
Q4 2021 Feb 14, 2022	BUY	$13.64 - $21.41 $1.78 Million - $2.8 Million	130,653 Added 61.74%	342,261 $7.33 Million
Q3 2021 Nov 15, 2021	BUY	$13.99 - $20.03 $329,030 - $471,085	23,519 Added 12.5%	211,608 $3.11 Million
Q2 2021 Aug 16, 2021	BUY	$19.02 - $29.78 $3.58 Million - $5.6 Million	188,089 New	188,089 $3.74 Million

Others Institutions Holding DSGN

# of Institutions

Shares Held

30.5M

Call Options Held

100

Put Options Held

100

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $187M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Design Therapeutics, Inc. Transaction History